Pimavanserin (Nuplazid)


FDA Approved Indications:
  • Treatment of hallucinations and delusions associated with Parkinson's disease psychosis
Prior authorization criteria:
  • Prescribed by or in collaboration with a specialist (neurologist or psychiatrist), AND
  • Diagnosis of Parkinson's disease with hallucinations and delusions, AND
  • Dose of 34mg once daily
  • Not recommended in patients with severe renal impairment (CrCL < 30mL/min), or hepatic impairment
Reauthoriztion criteria:
  • Medical record documentation supporting progress on medication
  • Recommended dose is 34mg, taken orally as two 17 mg tablets once daily, without titration
  • Initial: 3 months




WHA is closely monitoring the Coronavirus Disease 2019 (COVID-19). Learn more about COVID-19.